Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given

Size: px
Start display at page:

Download "Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given"

Transcription

1 Chapter 5 Gastroenterology Georgia Woodfield TERLIPRESSIN CIPROFLOXACIN 2 initial dose 500 Every 4 hours until bleeding controlled can be reduced to 1 after initial dose if side effects develop or if patient is <50 kg Normal duration of treatment is for 72 hours (or until haemostasis is achieved) Twice daily Can be given at a dose of 400. However, as it is the GI tract that is the target in this instance and additionally it is very irritant to veins, the oral route is preferential. Can cause hypertension and hypotension, which may already be present in a patient with haemorrhagic shock. This limits its use. Caution in patients with heart disease (due to it decreasing cardiac output). Can cause prolonged QT interval. OMEPRAZOLE 20 40, can be given (if active bleeding ulcer seen at oesophagogastroduodenoscopy) Generally given at the higher dose in this situation of confirmed peptic ulcer on endoscopy. In of severe recurrent ulceration, e.g. Zollinger Ellison syndrome, the dose can be up to 120 per day (divided doses). Essential Practical Prescribing, First Edition. Georgia Woodfield, Benedict Lyle Phillips, Victoria Taylor, Amy Hawkins and Andrew Stanton by John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.

2 LANSOPRAZOLE Generally given at the higher dose in this situation of confirmed peptic ulcer on endoscopy. May be used instead of omeprazole where there are intolerances or known drug interactions, e.g. omeprazole and clopidogrel (should be switched to lansoprazole if on clopidogrel). PANTOPRAZOLE 80 stat then 8 /h for 72 hours then infusion Stat then as an infusion over (up to) 72 hours This is given after acute GI bleed where the patient is still obtunded or shocked, and therefore would not tolerate oral medication. Can also be given orally as a tablet PROPRANOLOL for variceal bleed 40 BD Increase to 80 BD if blood pressure will allow Long-acting propranolol at either 80 or 160 can be used to improve compliance. HYDROCORTISONE 100 QDS Higher doses of steroids offer no greater benefit, but lower doses are less effective (Mowat et al., 2011). Intravenous steroids are generally given for up to 5 days. There is no benefit beyond 7 10 days (Turner et al., 2007). ENOXAPARIN 40 SC needs reduction in renal failure to 20, or where CrCl is very low, 50 units BD heparin SC may be substituted.

3 METRONIDAZOLE 400 TDS Can be given (500 TDS) if oral is not tolerated. Causes nausea and taste disturbances. Has a disulfiram-like reaction with alcohol. Metronidazole is an enzyme inhibitor and may therefore interact with other medications, notably warfarin. reduction in severe hepatic impairment: give 400 () or 500 () once daily. VANCOMYCIN 125 /NG QDS can be increased to 500 QDS in patients who are worsening or have signs of severe colitis. Intracolonic vancomycin (500 in ml saline 4 12 hourly) can be given as a retention enema. This involves administering the drug via a Foley catheter per rectum with the 30 ml balloon inflated and catheter clamped. After 60 minutes the balloon is deflated and catheter removed (Apisarnthanarak et al., 2002). The make-up of this prescription is an powder for reconstitution; however, it is licensed to give this compound orally for C. difficile treatment. FIDAXOMICIN 200 Twice daily Give for days.

4 LACTULOSE for hepatic encephalopathy ml BD Titrate up to keep bowels moving twice daily. VITAMIN K 10 Usually given for 3 consecutive days to ensure adequate replacement (Amarapurkar and Amarapurkar, 2011) None SENNA 1 2 tablets Tablets Best taken at night but can be twice daily Takes 8 12 hours to work, hence night-time regimen is best. LACTULOSE ml ml Up to TDS Takes hours to exert its effect. LYETHYLENE GLYCOL (Movicol ) ISPAGHULA HUSK (Fybogel ) 1 3 sachets 1 2 sachets, containing 3.5 g of ispaghula husk granules Up to four sachets per day Can cause flatulence and abdominal distension. Laxatives should not be given in cases of bowel obstruction. Up to TDS Movicol comes in lemon or chocolate flavour. 1 sachet is dissolved in half a glass of water (approximately 125 ml). 8 sachets can be given in 1 day for faecal impaction, this should be for short-term use only at this high dosage.

5 CITRAMAG and SENNA for bowel prep 1 sachet Citramag (magnesium citrate) at 4 pm and 8 pm the day before the procedure 10 tablets of senna at 4 pm the day before At 4 pm and 8 pm the day before the procedure or, if patient s procedure is later on the morning, 1 sachet at 8 pm the day before and again at 8 am the morning of the procedure These timings will vary according to Trust protocol The patient must adhere to a clear fluid diet the day before the procedure, then nil by mouth from midnight. This advice varies according to the Trust and according to the timing of the endoscopy. Some centres may recommend a low-residue diet for 3 5 days prior to the colonoscopy. According to the centre, this regimen also may vary when a patient has significant comorbidities such as renal or heart failure. These patients may have the senna omitted, or may have moviprep ( a polyethylene glycol solution) instead of Citramag.

BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM. 1 April 13

BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM. 1 April 13 BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM 1 BNF 1.1 ANTACIDS Mucogel and Peptac are effective antacids and are available over the counter Gaviscon / Gaviscon Advance are available over the counter First

More information

Understanding your take home medications from the surgical ward. Information for Patients

Understanding your take home medications from the surgical ward. Information for Patients Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for

More information

Dose. Route. Units. Given. Dose. Route. Units. Given

Dose. Route. Units. Given. Dose. Route. Units. Given Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening

More information

Rpts. GENERAL General Schedule (Code GE)

Rpts. GENERAL General Schedule (Code GE) Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form

More information

A patient s guide to the. management of constipation following surgery

A patient s guide to the. management of constipation following surgery A patient s guide to the management of constipation following surgery This leaflet has been designed to give you more information about using laxatives after your surgery. What is constipation? After your

More information

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

Gastro-intestinal System

Gastro-intestinal System CHAPTER 1 GASTRO-INTESTINAL SYSTEM 1.1 Nil by mouth patients drug administration Patients for investigations e.g. OGD (endoscopy): administer usual medicines with a sip of water caution with medicines

More information

Primary Care Constipation Guidelines. Version 1 November 2016

Primary Care Constipation Guidelines. Version 1 November 2016 Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and

More information

MOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l

MOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l MOVICOL -Half Powder for Solution (macrogol 3350) Product Name: Product Description: MOVICOL-Half Each sachet of MOVICOL-Half contains: Macrogol 3350 6.563 g Sodium chloride 175.4 mg Sodium bicarbonate

More information

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000 Package leaflet: Information for the user 10 g powder for oral solution in sachet Macrogol 4000

More information

Clostridium difficile Infection Antibiotics Guidelines. Contents

Clostridium difficile Infection Antibiotics Guidelines. Contents Clostridium difficile Infection Antibiotics Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

Gastrointestinal system

Gastrointestinal system Gastrointestinal system Medicines Formulary Contents: 1. Dyspepsia and gastro-oesophageal disease 1 2. Acute gastrointestinal bleeding 2 3. Irritable bowel syndrome 3 4. Diarrhoea 3 5. Inflammatory bowel

More information

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations Chapter 3 Cardiology Georgia Woodfield ASPIRIN FONDAPARINUX 300 once only in acute MI 75 in primary/ secondary prevention of thrombus formation and thromboembolic disease or PR; can also be given via nasogastric

More information

BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM

BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM 1 ANTACIDS Maalox and Peptac are effective antacids that can be bought Over the Counter for self-limiting symptoms. Choice Product Cost Effective Options &Comments

More information

MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)

MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Chocolate Flavour Product Description: Each sachet of MOVICOL Junior Chocolate contains: Macrogol 3350

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients: SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Macrovic Junior powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

Colonoscopy Preparation. Daniel Sussman, MD 19 February 2010 SGNA Course

Colonoscopy Preparation. Daniel Sussman, MD 19 February 2010 SGNA Course Colonoscopy Preparation Daniel Sussman, MD 19 February 2010 SGNA Course Objectives Importance of preparation Types of preps Comparative evidence behind prep choice Efficacy Tolerability Safety profiles

More information

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution. SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Molaxole powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains following active substances Macrogol

More information

MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350)

MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Lemon-Lime Flavour Product Description: Each sachet of MOVICOL Lemon-Lime contains: Macrogol 3350 Sodium chloride Sodium

More information

Guidelines for the Management of Constipation: Adult Patients

Guidelines for the Management of Constipation: Adult Patients Guidelines for the Management of Constipation: Adult Patients This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active

More information

PRODUCT INFORMATION RESONIUM A. Na m

PRODUCT INFORMATION RESONIUM A. Na m PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION

More information

Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)

Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol

More information

Axitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.

Axitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD. Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

Objectives Brand name Generic name Primary indication, drug classes Dosage forms Patient counseling information Important side effects and contraindic

Objectives Brand name Generic name Primary indication, drug classes Dosage forms Patient counseling information Important side effects and contraindic laxatives Hawler medical university Collage of pharmacy/ fourth stage /pharmacy practice Sham A. Talat Shareef (B.Sc. Msc. clinical pharmacy) 2017-2018 Sham_talat@yahoo.com Head of Department Of Clinical

More information

SUBMISSION FOR RECLASSIFICATION

SUBMISSION FOR RECLASSIFICATION SUBMISSION FOR RECLASSIFICATION OF SODIUM PICOSULPHATE (PICOPREP Powder) July 2002 Submission Prepared by: Contact: Baxter Healthcare Ltd. Auckland Mr. Alan Stanley Technical Manager - 1 - PART A 1. International

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding 1.1 Short title Acute upper GI bleeding

More information

POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS

POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS CLINICAL GASTROENTEROLOGY GEORGE Y. WU, SERIES EDITOR For other titles published in this series, go to www.springer.com/series/7672 POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS

More information

MOVICOL Junior Powder for Solution (macrogol 3350)

MOVICOL Junior Powder for Solution (macrogol 3350) MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

Package Insert. Constipeg

Package Insert. Constipeg Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF

More information

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve Treat primary symptoms Background information for clinicians Offer general lifestyle advice Background information for patients Manage IBS according to the dominant symptom Provenance Psychological symptoms

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf

More information

Chapter 1 Gastro-Intestinal System

Chapter 1 Gastro-Intestinal System Chapter 1 page number 1 Chapter 1 Gastro-Intestinal System First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both primary

More information

BJF Acute Pain Team Formulary Group

BJF Acute Pain Team Formulary Group Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution

More information

REFERENCE NUMBER: NH.PMN.47 EFFECTIVE DATE: 11/11

REFERENCE NUMBER: NH.PMN.47 EFFECTIVE DATE: 11/11 PAGE: 1 of 5 RETIRED: REVIEWED: 11/11, 12/14, 08/16, 07/17 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough

More information

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August BRAND NAME Symproic GENERIC NAME Naldemedine MANUFACTURER Shionogi Inc. DATE OF APPROVAL March 23, 2017 PRODUCT LAUNCH DATE Anticipated to launch mid-summer 2017 REVIEW TYPE Review type 1 (RT1): New Drug

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g

More information

Colonoscopy. In the work-up of intestinal disorders For prevention and early recognition of colon cancer

Colonoscopy. In the work-up of intestinal disorders For prevention and early recognition of colon cancer The informed patient Colonoscopy In the work-up of intestinal disorders For prevention and early recognition of colon cancer How do I prepare for the examination? How is the examination performed? Colonoscopy

More information

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine

More information

Inhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children

Inhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children Inhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children Link to: Adult Nebuliser Guidelines Link to: Paediatric Nebuliser Guidelines and Monographs ANTIBIOTICS/

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, October 2007 Doc. Ref. EMEA/527934/2007 ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER The Paediatric Working Party

More information

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection

More information

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000 Package leaflet: Information for the user Omnilax 10 g powder for oral solution, sachet Macrogol 4000 Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Prescribing Guidance for the Treatment of Constipation in Children

Prescribing Guidance for the Treatment of Constipation in Children Prescribing Guidance for the Treatment of Constipation in Children Effective Date: July 2007 Reviewed: September 2009 & December 2011 Review Date: December 2013 Gateshead Medicines Management Approved

More information

BNF CHAPTER 1: GASTROINTESTINAL

BNF CHAPTER 1: GASTROINTESTINAL BNF CHAPTER 1: GASTROINTESTINAL 1.1 DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE For symptomatic relief of hyperacidity, peptic ulcers, oesophagitis and acid reflux, liquids usually act faster than

More information

Pharmacy Benefit Determination Policy

Pharmacy Benefit Determination Policy Policy Subject: Opioid Induced Constipation Policy Number: SHS PBD11 Category: GI Agents Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS

More information

Package Leaflet: Information for the User

Package Leaflet: Information for the User Package Leaflet: Information for the User KLEAN-PREP 69g Sachet Powder for Oral Solution Macrogol 3350, Sodium sulphate anhydrous, Sodium bicarbonate, Sodium chloride and Potassium chloride Read all of

More information

Sample. Fractured Hip Post-Operative Orders. Legend < Mandatory fields o Optional fields. Height Allergies: List or o Up to date in electronic system

Sample. Fractured Hip Post-Operative Orders. Legend < Mandatory fields o Optional fields. Height Allergies: List or o Up to date in electronic system Legend Mandatory fields o Optional fields Height Allergies: List or o Up to date in electronic system cm Weight Diagnosis kg Date (yyyy-mon-dd) Time (hh:mm) Anticipated Date Of Discharge (ADOD) o Greater

More information

Mycophenolate Mofetil (MMF)

Mycophenolate Mofetil (MMF) SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in

More information

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides Package leaflet: Information for the user SenEase 7.5 mg tablets Sennosides Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep

More information

What Questions Should You Ask?

What Questions Should You Ask? ? Your Doctor Has Ordered a Colonoscopy. What Questions Should You sk? From the merican College of Gastroenterology www.acg.gi.org Normal colon Is the doctor performing your colonoscopy a Gastroenterologist?

More information

Ketorolac injection. Supportive care

Ketorolac injection. Supportive care Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is

More information

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice. Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnilax 10 g powder for oral solution, sachet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 10 g of macrogol 4000.

More information

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual

More information

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients: SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

More information

Irinotecan Capecitabine (14 day regimen) (I-Cap)

Irinotecan Capecitabine (14 day regimen) (I-Cap) Systemic Anti Cancer Treatment Protocol Irinotecan (14 day regimen) (I-Cap) PROTOCOL REF: MPHAICAP (Version No: 1.0) Approved for use in: Advanced colorectal cancer first line Advanced colorectal cancer

More information

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable

More information

1 of 5. Integrated Order Set Inpatient, Adult. Gynecological Surgery Enhanced Recovery Orders apply to patients 18 years and older.

1 of 5. Integrated Order Set Inpatient, Adult. Gynecological Surgery Enhanced Recovery Orders apply to patients 18 years and older. Orders apply to patients 18 years and older. All preprinted doses are based on normal renal and hepatic function and must be assessed for adjustment against the individual patient s renal and hepatic function

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact ame and Job Title (author) Directorate & Speciality Date of submission December 2015 Date on which guideline

More information

GASTRO-INTESTINAL SYSTEM 1.1 Dyspepsia and gastro-oesophageal reflux disease

GASTRO-INTESTINAL SYSTEM 1.1 Dyspepsia and gastro-oesophageal reflux disease Original Date of issue: 05/04/07 Last eviewed: 08/03/2013 Version: 5 Page 1 of 11 GASTO-INTESTINAL SYSTEM 1.1 Dyspepsia and gastro-oesophageal reflux disease 1.1.1 Antacids and simeticone Magnesium Trisilicate

More information

Trust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)

Trust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over) Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical

More information

RYAN CRENSHAW, M.D. Instructions for Colonoscopy with MoviPrep

RYAN CRENSHAW, M.D. Instructions for Colonoscopy with MoviPrep RYAN CRENSHAW, M.D. Instructions for Colonoscopy with MoviPrep Please read 2 weeks prior to your procedure. If you fail to follow the instructions and the procedure has to be cancelled, the cancellation

More information

Gastrointestinal Involvement in Adult Mitochondrial Disease

Gastrointestinal Involvement in Adult Mitochondrial Disease Newcastle Mitochondrial Disease Guidelines At a glance guidelines: Gastrointestinal Involvement in Adult Mitochondrial Disease For full guideline visit: http://www.newcastle-mitochondria.com/service/patient-care-guidelines/

More information

Medicines for people having dialysis

Medicines for people having dialysis Patient Information: Medicines NHS Logo here Medicines for people having dialysis Health & care information you can trust The Information Standard Certified Member Working together for better patient information

More information

VIP (Etoposide, Ifosfamide and Cisplatin)

VIP (Etoposide, Ifosfamide and Cisplatin) VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate

More information

CARD OPEN HEART PRE-OP PLAN

CARD OPEN HEART PRE-OP PLAN PHYSICIAN S Diagnosis Weight Allergies Patient Care Perform Oral Care Per Unit Standards, Perform night before surgery. Brush teeth with toothpaste. Peridex mouth wash (15 ml swish and spit). chlorhexidine

More information

Peptic ulcer disease Disorders of the esophagus

Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth

More information

Antidiarrheals Antidiarrheal

Antidiarrheals Antidiarrheal Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

PACKAGE LEAFLET: Information for the patient. METRONIDAZOL Tablets 250 mg Solution for infusion 0.5 % Ovules mg (Metronidazole)

PACKAGE LEAFLET: Information for the patient. METRONIDAZOL Tablets 250 mg Solution for infusion 0.5 % Ovules mg (Metronidazole) PACKAGE LEAFLET: Information for the patient METRONIDAZOL Tablets 250 mg Solution for infusion 0.5 % Ovules - 500 mg (Metronidazole) Read this leaflet carefully before you start taking this medicine. Keep

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 June 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 June 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 June 2010 COLOKIT, tablets B/32 (CIP: 347 188-1) Applicant: MAYOLY SPINDLER Monosodium phosphate monohydrate Anhydrous

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

Report generated from MPH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number.

Report generated from MPH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Report generated from MPH provided by Complete (www.pharmpress.com). Accessed 15 01 2016 Title Status Section TA Number TA Link Alu-Cap simeticone->aluminium- and magnesium-containing antacids->aluminium

More information

Palliative Prescribing - Pain

Palliative Prescribing - Pain Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing

More information

Sunitinib (renal) ICD-10 codes Codes with a prefix C64

Sunitinib (renal) ICD-10 codes Codes with a prefix C64 Sunitinib (renal) Indication First line treatment of patients with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG)

More information

Cabozantinib (Cabometyx )

Cabozantinib (Cabometyx ) Cabozantinib (Cabometyx ) Indication Treatment of advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF) targeted therapy. (NICE TA463) Treatment of previously untreated

More information

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults Co-ordinators: Medicines Information Pharmacist Consultation Group: See relevant page in guidance Approver: Medicine Guidelines

More information

MOVIPREP. Morning Appointment. Information for patients. Endoscopy Unit

MOVIPREP. Morning Appointment. Information for patients. Endoscopy Unit Endoscopy Unit MOVIPREP Morning Appointment Information for patients Please follow these instructions and NOT the instructions in the box of bowel prep medication that you have been sent This leaflet contains

More information

Algorithms for Symptom Management. In End of Life Care

Algorithms for Symptom Management. In End of Life Care Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the

More information

Guideline scope Diverticular disease: diagnosis and management

Guideline scope Diverticular disease: diagnosis and management NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Diverticular disease: diagnosis and management The Department of Health in England has asked NICE to develop a clinical guideline on diverticular

More information

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name

More information

Clinical guideline Published: 13 June 2012 nice.org.uk/guidance/cg141

Clinical guideline Published: 13 June 2012 nice.org.uk/guidance/cg141 Acute upper gastrointestinal bleeding in over 16s: management Clinical guideline Published: June 2012 nice.org.uk/guidance/cg141 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics

More information

2 Gastrointestinal Bleeding

2 Gastrointestinal Bleeding 2 Gastrointestinal Bleeding Lisa Rossi, MD and Shishir Mathur, MBBS C ONTENTS Acute Non-Variceal Upper Gastrointestinal Bleeding Acute Hemorrhage from Esophageal Varices ACUTE NON-VARICEAL UPPER GASTROINTESTINAL

More information

Getting Ready for Your Colonoscopy

Getting Ready for Your Colonoscopy Getting Ready for Your Colonoscopy Exam Arrival Date and Time: Exam performed by Dr. Brigham and Women s Hospital Endoscopy Center 75 Francis Street Amory Building, 2 nd Floor Boston, MA 02115 Brigham

More information

EDWARD J. SHARE, M.D. COLONOSCOPY SCREENING

EDWARD J. SHARE, M.D. COLONOSCOPY SCREENING EDWARD J. SHARE, M.D. CEDARS-SINAI MEDICAL OFFICE TOWERS 8631 W. THIRD ST. SUITE 1015E LOS ANGELES, CALIFORNIA 90048 PHONE 310-652-4472 FAX 310-358-2266 GASTROENTEROLOGY AND HEPATOLOGY COLONOSCOPY SCREENING

More information